The COVID crisis has impacted IPM negatively – the growth seen in July 2020 was a mere 0.2%. This is down to -2.2% de-growth in August 2020 and shows a single digit growth of 4.1% on a MAT basis.
#Cardiac has stabilized but with lower growth of 11.5% in August 2020 – compared to 13.1% in July 2020. On a MAT basis, the growth is 11.6%.
Anti-Diabetic had a growth of 1.6 % in August 2020 compared to 5.9% in July 2020. On a MAT basis the is growth is 8.4%.
#Respiratory segment in on a #ventilator, and the growth slumped to -12.4 % compared to -2% in July 2020. On a MAT basis, the growth is 7.9%.
Anti-infectives de-grew at -10.2 % in July 2020 and continues the negative trend at -11 % in August 2020. On a MAT basis, the growth is 0.1%.
#Gastro had shown a de-growth of -2.4 % in July 2020 and this has further slipped to 3.1% in August 2020. On a MAT basis, the growth is a mere 1.7%.
#Vitamins had bounced back with a growth of 5.5% in July 2020 and continues the growth trend at 6.2 % in August 2020. On a MAT basis, the growth is 4.4%.
#Pain & #Analgesics were struggling at -6.7% in July 2020 and continues the downward trend at -9.8 % in August 2020. On a MAT basis, the growth is a mere 0.4%.
Source: PharmaTrac AIOCD AWACS
